Abstract:The existence of eosinophils was documented histopathologically in the first half of the 19th century. However, the term "eosinophils" was first used by Paul Ehrlich in 1878. Since their discovery and description, their existence has been associated with asthma, allergies, and antihelminthic immunity. Eosinophils may also be responsible for various possible tissue pathologies in many eosinophil-associated diseases. Since the beginning of the 21st century, the understanding of the nature of this cell population has undergone a fundamental reassessment, and in 2010, J. J. Lee proposed the concept of "LIAR" (Local Immunity And/or Remodeling/Repair), underlining the extensive immunoregulatory functions of eosinophils in the context of health and disease. It soon became apparent that mature eosinophils (in line with previous morphological studies) are not structurally, functionally, or immunologically homogeneous cell populations. On the contrary, these cells form subtypes characterized by their further development, immunophenotype, sensitivity to growth factors, localization, role and fate in tissues, and contribution to the pathogenesis of various diseases, including asthma. The eosinophil subsets were recently characterized as resident (rEos) and inflammatory (iEos) eosinophils. During the last 20 years, the biological therapy of eosinophil diseases, including asthma, has been significantly revolutionized. Treatment management has been improved through the enhancement of treatment effectiveness and a decrease in the adverse events associated with the formerly ultimately used systemic corticosteroids. However, as we observed from real-life data, the global treatment efficacy is still far from optimal. A fundamental condition, "sine qua non", for correct treatment management is a thorough evaluation of the inflammatory phenotype of the disease. We believe that a better understanding of eosinophils would lead to more precise diagnostics and classification of asthma subtypes, which could further improve treatment outcomes. The currently validated asthma biomarkers (eosinophil count, production of NO in exhaled breath, and IgE synthesis) are insufficient to unveil super-responders among all severe asthma patients and thus give only a blurred picture of the adepts for treatment. We propose an emerging approach consisting of a more precise characterization of pathogenic eosinophils in terms of the definition of their functional status or subset affiliation by flow cytometry. We believe that the effort to find new eosinophil-associated biomarkers and their rational use in treatment algorithms may ameliorate the response rate to biological therapy in patients with severe asthma.

SEC14-like 3 is Decreased in Airway Ciliated Cells in Experimental and Paediatric Asthma

miRNA-based identification of SEC14L3 deregulation in murine experimental asthma

MicroRNA in Children with Asthma: Findings from Bronchoalveolar Lavage Fluid

Pulmonary Microrna Profiles Identify Involvement of Creb1 and Sec14l3 in Bronchial Epithelial Changes in Allergic Asthma

A cellular census of healthy lung and asthmatic airway wall identifies novel cell states in health and disease

A cellular census of human lungs identifies novel cell states in health and in asthma

Urinary Metabolomic Profiling Reveals Biological Pathways and Predictive Signatures Associated with Childhood Asthma

Clinical Significance of Combined Detection of CCL22 and IL‐1 as Potential New Bronchial Inflammatory Mediators in Children's Asthma

Identification and treatment of persistent small airway dysfunction in paediatric patients with asthma: a retrospective cohort study

Small Airways Disease Affects Aerosol Deposition in Children with Severe Asthma: A Functional Respiratory Imaging Study

Proteomic Analysis of Sputum Reveals Novel Biomarkers for Various Presentations of Asthma.

Age-Dependent Allergic Asthma Development and Cystathionine Gamma-Lyase Deficiency.

Clinical efficacy of recombinant human latrophilin 3 antibody in the treatment of pediatric asthma

Subsets of Eosinophils in Asthma, a Challenge for Precise Treatment

The role of 14-3-3β in acute asthma in children and analysis of the risk factors for asthma exacerbation

Innate players in Th2 and non-Th2 asthma: emerging roles for the epithelial cell, mast cell, and monocyte/macrophage network

Pediatric asthma: An unmet need for more effective, focused treatments

Pathway Discovery Using Transcriptomic Profiles in Adult-Onset Severe Asthma.

New insights in small airway dysfunction of childhood asthma

Early infancy microbial and metabolic alterations affect risk of childhood asthma

The monitor and clinical significance of small airways function in children with asthma in remission stage